References
- Arber DA, Orazi A, Hasserjian RP, et al. Introduction and overview of the classification of myeloid neoplasms. In: Swerdlow SH, Campo E, Harris NL, editors. WHO classification of tumors of haematopoietic and lymphoid tissues, 2017 revised edition. Lyon: International Agency for Research on cancer (IARC); 2017. p. 16–27.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer. J Clin. 2019;69:7–34. doi:https://doi.org/10.3322/caac.21551.
- Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113:4179–4187. DOI:https://doi.org/10.1182/blood-2008-07-172007.
- De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6:e441, DOI:https://doi.org/10.1038/bcj.2016.50.
- Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–447. DOI:https://doi.org/10.1182/blood-2016-08-733196.
- Tallman MS, Wang ES, Altman JK, et al. Acute myeloid leukemia version 3.2019. J Natl Compr Canc Netw. 2019;17:721–749. DOI:https://doi.org/10.6004/jnccn.2019.0028.
- Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361:13;1249–1259. DOI:https://doi.org/10.1056/NEJMoa0904544.
- Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med. 1994;331:896–903.
- Schaich M, Rollig C, Soucek S M, et al. Cytarabine dose of 36 g/m2 compared with 12 g/m2 within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. J Clin Oncol. 2011;29:2696–2702. DOI:https://doi.org/10.1200/JCO.2010.33.7303.
- Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol. 2013;31:3360–3368. DOI:https://doi.org/10.1200/JCO.2012.47.4874.
- Wu D, Duan C, Chen L, et al. Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis. Sci Rep. 2017;7:9509, DOI:https://doi.org/10.1038/s41598-017-10368-0.
- U.S. Department of Health and Human Service. National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 November 27, 2017 [cited 2018 April 13]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf
- Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.
- Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56–e93. DOI:https://doi.org/10.1093/cid/cir073.
- Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301:2349–2361. DOI:https://doi.org/10.1001/jama.2009.813.
- Owattanapanich W, Utchariyaprasit E, Tantiworawit A, et al. Improved survival of elderly-fit patients with acute myeloid leukemia requiring intensive therapy: 3-year multicenter analysis from TALWG. Clin Lymphoma Myeloma Leuk. 2018: e509–e514. DOI:https://doi.org/10.1016/j.clml. cited 2018.08.002.
- Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58:4173–4179.
- Miyawaki S, Ohtake S, Fujisawa S, et al. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 study. Blood. 2011;117:2366–2372. DOI:https://doi.org/10.1182/blood-2010-07-295279.
- Gong D, Li W, Hu LD, et al. Comparison of clinical efficacy of cytarabine with different regimens in postremission consolidation therapy for adult t(8;21) AML patients: A multicenter retrospective study in China. Acta Haematol. 2016;136:201–209. DOI:https://doi.org/10.1159/000448209.
- Schaich M, Parmentier S, Kramer M, et al. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. J Clin Oncol. 2013;31:2094–2102. DOI:https://doi.org/10.1200/JCO.2012.46.4743.
- Zhou JH, Lin HQ, Shen Q, et al. Comparison of mitoxantrone in combination with intermediate-dose cytarabine versus high-dose cytarabine as consolidation therapies for young non-APL acute myeloid leukemia patients with favorable and intermediate cytogenetics. Curr Med Sci. 2018;38:51–57. DOI:https://doi.org/10.1007/s11596-018-1845-x.
- Kim DS, Kang KW, Lee SR, et al. Comparison of consolidation strategies in acute myeloid leukemia: high-dose cytarabine alone versus intermediate-dose cytarabine combined with anthracyclines. Ann Hematol. 2015;94:1485–1492. DOI:https://doi.org/10.1007/s00277-015-2389-9.